Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has shared an update.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has convened its 2025 annual general meeting for May 21, 2026, to be held both physically in Beijing and virtually online. Shareholders will review the board’s 2025 work report and vote on reappointing KPMG as auditor for 2026, as well as setting directors’ remuneration and approving the 2025 profit distribution plan.
The AGM agenda also includes confirming 2025 related party transactions and approving estimated related party dealings for 2026, along with a special resolution on comprehensive credit facilities and guarantees for the company and its subsidiaries. Investors will further consider changes to the company’s registered capital and amendments to its Articles of Association, while receiving the 2026 senior management remuneration plan and the 2025 report from independent non-executive directors, signaling governance and capital-structure decisions that may shape Biocytogen’s financing and operational flexibility.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. is a PRC-incorporated biopharmaceutical company listed in Hong Kong under stock code 2315. The company operates in the life sciences and drug development industry, focusing on pharmaceutical R&D and related services from its base in Beijing’s Daxing Bio-Medicine Industry Park.
Average Trading Volume: 1,584,002
Technical Sentiment Signal: Buy
Current Market Cap: HK$23.33B
For a thorough assessment of 2315 stock, go to TipRanks’ Stock Analysis page.